COMPANY

Palisade Bio

HQ: Denver, CO source · palisadebio.com ↗ · Mountain

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapeutics for immune-mediated and fibrotic diseases. From company website Source · checked 2026-10-19

Sources for this description (1)

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapeutics for immune-mediated and fibrotic diseases.
- “Palisade Bio is a clinical-stage biopharmaceutical company developing differentiated oral therapeutics for immune-mediated and fibrotic diseases.” https://palisadebio.com/about-us-overview/ (2026-10-19)

Therapeutic area: fibrotic diseases

Disease: ulcerative colitis crohn’s disease

Target: PDE4 inhibitor

Product: PALI-2108

Keywords: immunology fibrotic diseases inflammatory bowel disease Ileus Severe Ulcerative Colitis Moderate Ulcerative Colitis Fibrostenotic Crohn's Disease Post-Operative Adhesions Gastro-Intestinal Disorder LB1148

Location: Denver, CO · source · Oct 13, 2026

Profile checked Oct 10, 2026

$143.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

Aug 28, 2026 Trial start Phase 2: A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis source ↗
Jan 7, 2026 Raise Private placement: amount not published, announced Jan 7, 2026. Source: company release on GlobeNewswire. source ↗
Oct 17, 2025 Trial start Phase 1: A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease source ↗
Oct 2, 2025 Raise Follow-on offering: $138M (total, as published), announced Oct 2, 2025. Source: company release on GlobeNewswire. source ↗
Dec 13, 2024 Raise Follow-on offering: $5M (total, as published), announced Dec 13, 2024. Source: company release on GlobeNewswire. source ↗
Nov 5, 2024 Trial start 1: Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. source ↗
Jun 28, 2022 Trial start Phase 3: A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection source ↗
Oct 1, 2019 Trial start Phase 2: A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Phase 2 · A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis · NCT07845487

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $143.0M. Last 2 years.

Jan 7, 2026 Private placement: amount not published, announced Jan 7, 2026. Source: company release on GlobeNewswire. source ↗
Oct 2, 2025 Follow-on offering: $138M (total, as published), announced Oct 2, 2025. Source: company release on GlobeNewswire. source ↗
Dec 13, 2024 Follow-on offering: $5M (total, as published), announced Dec 13, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07845487	A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2	Recruiting	Aug 28, 2026	2027-10 (estimated)
NCT07428096	A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease	Phase 1	Active, not recruiting	Oct 17, 2025	Jan 30, 2026 (actual)
NCT06663605	Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.	1	Completed	Nov 5, 2024	Jul 7, 2025 (actual)
NCT02836470	A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection	Phase 2	Completed	Oct 1, 2019	Sep 6, 2023 (actual)
NCT05470387	A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection	Phase 3	Terminated	Jun 28, 2022	Mar 6, 2023 (actual)